The Pulmonary Tuberculosis drugs in development market research report provides comprehensive information on the therapeutics under development for Pulmonary Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pulmonary Tuberculosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pulmonary Tuberculosis and features dormant and discontinued products.
GlobalData tracks 28 drugs in development for Pulmonary Tuberculosis by 25 companies/universities/institutes. The top development phase for Pulmonary Tuberculosis is phase ii with 16 drugs in that stage. The Pulmonary Tuberculosis pipeline has 21 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Pulmonary Tuberculosis pipeline products market are: Global Alliance for TB Drug Development, Otsuka Pharmaceutical and Infectex.
The key targets in the Pulmonary Tuberculosis pipeline products market include FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase, H+ Transporting Two Sector ATPase, and 23S Ribosomal RNA.
The key mechanisms of action in the Pulmonary Tuberculosis pipeline product include FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase Inhibitor with four drugs in Phase II. The Pulmonary Tuberculosis pipeline products include seven routes of administration with the top ROA being Oral and eight key molecule types in the Pulmonary Tuberculosis pipeline products market including Small Molecule, and Subunit Vaccine.
Pulmonary Tuberculosis overview
Pulmonary tuberculosis (TB) is an infectious respiratory disease caused by Mycobacterium tuberculosis, capable of spreading to other organs. The bacterium is highly contagious, transmitted through air droplets from coughs or sneezes of infected individuals. Initial infection, known as primary TB, may be asymptomatic. When symptoms manifest, they encompass breathing difficulties, chest pain, cough with mucus, blood-tinged sputum, night sweats, fatigue, fever, weight loss, and wheezing. Treatment aims to cure the infection, typically involving a combination of four medications. Administered until lab tests indicate the most effective drugs, this approach addresses active pulmonary TB and underscores the importance of adherence for successful outcomes.
For a complete picture of Pulmonary Tuberculosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
